Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~-Has acne vulgaris on the face, including the nose, with 20 to 100 total lesions (noninflammatory and/or inflammatory).~Exclusion Criteria:~* Has uncontrolled systemic disease(s)~* Has severe cystic acne, acne conglobata, acne fulminans, or secondary acne (chloracne, drug-induced acne)~* Has used topical dapsone within 1 month prior to the screening~* Has used oral dapsone within 2 months prior to screening.

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- PK Cohort: ACZONE 7.5% (Type: EXPERIMENTAL): Participants applied ACZONE 7.5 % gel topically, once-daily to the entire face, neck, upper chest, upper back and shoulders starting from Day 1 under maximal use conditions (2 grams per day) for Day 8 consecutive days, followed by a thin layer to their face and acne-affected areas on the upper chest, upper back, and shoulders for next 11 weeks.
- Non-PK Cohort: ACZONE 7.5% (Type: EXPERIMENTAL): Participants applied ACZONE 7.5% gel topically, once-daily in a thin layer to their face and acne-affected areas on upper chest, upper back, and shoulders for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).